Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enliven Therapeutics (ELVN) Non Operating Income (2019 - 2025)

Enliven Therapeutics has reported Non Operating Income over the past 7 years, most recently at -$2000.0 for Q2 2025.

  • Quarterly results put Non Operating Income at -$2000.0 for Q2 2025, down 100.04% from a year ago — trailing twelve months through Mar 2026 was -$2000.0 (up 99.94% YoY), and the annual figure for FY2025 was -$49000.0, changed.
  • Non Operating Income reached -$2000.0 in Q2 2025 per ELVN's latest filing, up from -$47000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $4.7 million in Q2 2024 and bottomed at -$11.8 million in Q4 2024.
  • Median Non Operating Income over the past 5 years was $151500.0 (2021), compared with a mean of $64666.7.
  • Peak annual rise in Non Operating Income hit 18722.22% in 2023, while the deepest fall reached 1504.24% in 2023.
  • Over 5 years, Non Operating Income stood at $176000.0 in 2021, then soared by 248.3% to $613000.0 in 2022, then crashed by 1504.24% to -$8.6 million in 2023, then tumbled by 37.24% to -$11.8 million in 2024, then skyrocketed by 99.98% to -$2000.0 in 2025.
  • Business Quant data shows Non Operating Income for ELVN at -$2000.0 in Q2 2025, -$47000.0 in Q1 2025, and -$11.8 million in Q4 2024.